Left to Their Own Devices

Patrik Plöen, Legal Counsel, Q-Med, Sweden

The European Union (“EU”) has among its most fundamental goals and principles a convergence of the economies of, and a weakening of internal frontiers between, its member states . Economic integration, so conventional wisdom would have it, will increase the efficiency and competition within the internal market, lowering consumer prices and contributing to a more effective allocation and utilisation of resources. At least that is the theory. Given the development over the past couple of decades, whether those goals have been achieved is to a degree dependent upon your political point of view, but there can be no denying the convergence or harmonisation of significant amounts of national legislation throughout the EU.

Read full paper Subscribe to the IICJ
Sweden Regulation Pharmaceutical June 2010 Vol. 3, No. 11, Spring 2010

Patrik Plöen

More

Q-Med

More

Q-Med is a medical device company that primarily develops, manufactures, markets and sells medical implants. Most of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The company today has approximately 650 co-workers in 20 countries, with 385 at the company's head office and production facility in Uppsala. Q-Med had sales of 1,364 MSEK during 2009. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

Sweden Regulation Pharmaceutical June 2010 Vol. 3, No. 11, Spring 2010